Success Metrics

Clinical Success Rate

92.3%

Based on 12 completed trials

Completion Rate

92%(12/13)

Active Trials

36(62%)

Results Posted

100%(12 trials)

Terminated

1(2%)

Phase Distribution

Ph phase_4

Ph phase_3

16%

Ph phase_1

31%

Ph phase_2

43%

Ph early_phase_1

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution56 total trials

Early Phase 1First-in-human

1(1.8%)

Phase 1Safety & dosage

18(32.1%)

Phase 2Efficacy & side effects

25(44.6%)

Phase 3Large-scale testing

9(16.1%)

Phase 4Post-market surveillance

3(5.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

12 of 15 finished

Non-Completion Rate

20.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(42)

Completed(12)

Terminated(3)

Other(1)

Detailed Status

Recruiting27

Completed12

Active, not recruiting9

Not yet recruiting6

Withdrawn2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

92.3%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (1.8%)

Phase 118 (32.1%)

Phase 225 (44.6%)

Phase 39 (16.1%)

Phase 43 (5.4%)

Trials by Status

withdrawn23%

terminated12%

active_not_recruiting916%

recruiting2747%

completed1221%

not_yet_recruiting610%

unknown12%

Recent Activity

36 active trials

Showing 5 of 58

recruitingphase_2

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

active_not_recruitingphase_1

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541

recruitingphase_3

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

NCT07342478

recruitingphase_2

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

NCT05536349

active_not_recruitingphase_3

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT04666038

View all 58 trials

Clinical Trials (58)

Showing 20 of 58 trialsScroll for more

NCT05529069Phase 2

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Recruiting

NCT04623541Phase 1

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Active Not Recruiting

NCT07342478Phase 3

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Recruiting

NCT05536349Phase 2

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting

NCT04666038Phase 3

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active Not Recruiting

NCT06263491Phase 2

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Recruiting

NCT07548450Phase 2

Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)

Not Yet Recruiting

NCT06948786Phase 2

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Recruiting

NCT06973187Phase 3

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting

NCT06252675Phase 2

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Recruiting

NCT05254743Phase 3

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting

NCT06721013Phase 1

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Recruiting

NCT07218341Phase 4

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting

NCT07162181Phase 2

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Active Not Recruiting

NCT06522386Phase 2

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Active Not Recruiting

NCT07525817

A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma

Not Yet Recruiting

NCT07516093Phase 3

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Not Yet Recruiting

NCT06553872Phase 2

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Recruiting

NCT06588478Phase 2

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting

NCT07428707Early Phase 1

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

Recruiting

Drug Details

Intervention Type: DRUG
Total Trials: 58